These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34190685)

  • 1. Efficacy and safety of tedizolid in a patient with linezolid-induced neutropenia: A case report.
    Kobayashi S; Kase M; Matsubara M; Kitaoka A; Yasu T
    Int J Clin Pharmacol Ther; 2021 Sep; 59(9):627-629. PubMed ID: 34190685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Tolerability of More than Six Days of Tedizolid Treatment.
    Mensa Vendrell M; Tasias Pitarch M; Salavert Lletí M; Calabuig Muñoz E; Morata Ruiz L; Castells Lao G; López Suñé E; Mensa Pueyo J; Oltra Sempere MR; Pedro-Botet Montoya ML; Isernia V; Reynaga Sosa EA; Moreno Nuñez L; Pasquau Liaño J; Sequera Arquelladas S; Yuste Ara JR; Soriano Viladomiu A
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32312777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections.
    Hardalo C; Lodise TP; Bidell M; Flanagan S; De Anda C; Anuskiewicz S; Prokocimer P
    Expert Opin Drug Saf; 2018 Apr; 17(4):359-367. PubMed ID: 29528251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
    Moran GJ; Fang E; Corey GR; Das AF; De Anda C; Prokocimer P
    Lancet Infect Dis; 2014 Aug; 14(8):696-705. PubMed ID: 24909499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
    Lv X; Alder J; Li L; O'Riordan W; Rybak MJ; Ye H; Zhang R; Zhang Z; Zhu X; Wilcox MH
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid.
    Mikamo H; Nagashima M; Kusachi S; Fujimi S; Oshima N; De Anda C; Takase A
    J Infect Chemother; 2022 Sep; 28(9):1235-1241. PubMed ID: 35718656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections.
    Ortiz-Covarrubias A; Fang E; Prokocimer PG; Flanagan SD; Zhu X; Cabré-Márquez JF; Tanaka T; Passarell J; Fiedler-Kelly J; Nannini EC
    Braz J Infect Dis; 2016; 20(2):184-92. PubMed ID: 26859064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections
    Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P
    J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.
    McBride D; Krekel T; Hsueh K; Durkin MJ
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):331-337. PubMed ID: 28140693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Translational Pharmacokinetic/Pharmacodynamic Infection Models To Understand the Impact of Neutropenia on the Efficacy of Tedizolid Phosphate.
    Xiao J; Gill C; Liang L; Liu J; Wu J; Feng HP; Flanagan S; Tan C; Flattery A
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombocytopenia with Tedizolid and Linezolid.
    Lee EY; Caffrey AR
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
    Prokocimer P; De Anda C; Fang E; Mehra P; Das A
    JAMA; 2013 Feb; 309(6):559-69. PubMed ID: 23403680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Wunderink RG; Roquilly A; Croce M; Rodriguez Gonzalez D; Fujimi S; Butterton JR; Broyde N; Popejoy MW; Kim JY; De Anda C
    Clin Infect Dis; 2021 Aug; 73(3):e710-e718. PubMed ID: 33720350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.
    Shorr AF; Lodise TP; Corey GR; De Anda C; Fang E; Das AF; Prokocimer P
    Antimicrob Agents Chemother; 2015 Feb; 59(2):864-71. PubMed ID: 25421472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the haematological profile of 21 days of tedizolid in healthy subjects.
    Lodise TP; Bidell MR; Flanagan SD; Zasowski EJ; Minassian SL; Prokocimer P
    J Antimicrob Chemother; 2016 Sep; 71(9):2553-8. PubMed ID: 27317442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.
    Douros A; Grabowski K; Stahlmann R
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1849-59. PubMed ID: 26457865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections.
    Urbina O; Ferrández O; Espona M; Salas E; Ferrández I; Grau S
    Drug Des Devel Ther; 2013; 7():243-65. PubMed ID: 23589680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials.
    De Anda C; Anuskiewicz S; Prokocimer P; Vazquez J
    Medicine (Baltimore); 2017 Dec; 96(52):e9163. PubMed ID: 29384903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - Results of a randomised, multicentre phase 3 study.
    Mikamo H; Takesue Y; Iwamoto Y; Tanigawa T; Kato M; Tanimura Y; Kohno S
    J Infect Chemother; 2018 Jun; 24(6):434-442. PubMed ID: 29530544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.